Anti-IL2RA/ CD25/ IDDM10 monoclonal antibody

Anti-IL2RA/ CD25/ IDDM10 antibody for FACS & in-vivo assay

Target products collectionGo to IL2RA/IL2RA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T03313-Ab-1/ GM-Tg-hg-T03313-Ab-2Anti-Human IL2RA monoclonal antibodyHuman
GM-Tg-rg-T03313-Ab-1/ GM-Tg-rg-T03313-Ab-2Anti-Rat IL2RA monoclonal antibodyRat
GM-Tg-mg-T03313-Ab-1/ GM-Tg-mg-T03313-Ab-2Anti-Mouse IL2RA monoclonal antibodyMouse
GM-Tg-cynog-T03313-Ab-1/ GM-Tg-cynog-T03313-Ab-2Anti-Cynomolgus/ Rhesus macaque IL2RA monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T03313-Ab-1/ GM-Tg-felg-T03313-Ab-2Anti-Feline IL2RA monoclonal antibodyFeline
GM-Tg-cang-T03313-Ab-1/ GM-Tg-cang-T03313-Ab-2Anti-Canine IL2RA monoclonal antibodyCanine
GM-Tg-bovg-T03313-Ab-1/ GM-Tg-bovg-T03313-Ab-2Anti-Bovine IL2RA monoclonal antibodyBovine
GM-Tg-equg-T03313-Ab-1/ GM-Tg-equg-T03313-Ab-2Anti-Equine IL2RA monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T03313-Ab-1/ GM-Tg-hg-T03313-Ab-2; GM-Tg-rg-T03313-Ab-1/ GM-Tg-rg-T03313-Ab-2;
GM-Tg-mg-T03313-Ab-1/ GM-Tg-mg-T03313-Ab-2; GM-Tg-cynog-T03313-Ab-1/ GM-Tg-cynog-T03313-Ab-2;
GM-Tg-felg-T03313-Ab-1/ GM-Tg-felg-T03313-Ab-2; GM-Tg-cang-T03313-Ab-1/ GM-Tg-cang-T03313-Ab-2;
GM-Tg-bovg-T03313-Ab-1/ GM-Tg-bovg-T03313-Ab-2; GM-Tg-equg-T03313-Ab-1/ GM-Tg-equg-T03313-Ab-2
Products NameAnti-IL2RA monoclonal antibody
Formatmab
Target NameIL2RA
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IL2RA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-907Pre-Made Melredableukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2 (interleukin 2, IL-2) via a peptidyl linker: Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55
    BiosimilarGMP-Bios-INN-926Pre-Made Nemvaleukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165): Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55
    BiosimilarGMP-Bios-INN-768Pre-Made Camidanlumab Tesirine Biosimilar, Whole Mab Adc, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-INN-789Pre-Made Daclizumab Beta Biosimilar, Whole Mab, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
    BiosimilarGMP-Bios-ab-129Pre-Made Daclizumab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
    BiosimilarGMP-Bios-ab-049Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
    BiosimilarGMP-Bios-INN-867Pre-Made Inolimomab Biosimilar, Whole Mab, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
    BiosimilarGMP-Bios-ab-089Pre-Made Camidanlumab biosimilar, Whole mAb ADC, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species IL2RA/ CD25/ IDDM10 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLP002911human IL2RA Lentivirus plasmid
    ORF Viral VectorvGMLP002911human IL2RA Lentivirus particle
    ORF Viral VectorpGMLPm001587mouse Il2ra Lentivirus plasmid
    ORF Viral VectorvGMLPm001587mouse Il2ra Lentivirus particle


    Target information

    Target IDGM-T03313
    Target NameIL2RA
    Gene ID3559,16184,25704,574300,403870,493953,281861,100070292
    Gene Symbol and SynonymsCD25,IDDM10,IL-2RA,IL2R,IL2RA,IL2RAC,IMD41,Ly-43,p55,TCGFR
    Uniprot AccessionP01589,P26897,Q5MNY4,O62802,P41690,P12342
    Uniprot Entry NameIL2RA_HUMAN,IL2RA_MACMU,IL2RA_RAT,IL2RA_FELCA,IL2RA_CANLF,IL2RA_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseOvary Cancer
    Gene EnsemblENSG00000134460
    Target ClassificationCheckpoint-Immuno Oncology

    The target: IL2RA, gene name: IL2RA, also named as CD25, IDDM10, IL2R, IMD41, TCGFR, p55. The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. Patients with severe Coronavirus Disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have significantly elevated levels of IL2R in their plasma. Similarly, serum IL-2R levels are found to be elevated in patients with different types of carcinomas. Certain IL2RA and IL2RB gene polymorphisms have been associated with lung cancer risk. [provided by RefSeq, Jul 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.